CO6230989A2 - Compuestos de quinolina apropiados para tratar transtornos que responden a la modulacion del receptor de serotonina 5-ht6 - Google Patents
Compuestos de quinolina apropiados para tratar transtornos que responden a la modulacion del receptor de serotonina 5-ht6Info
- Publication number
- CO6230989A2 CO6230989A2 CO09103181A CO09103181A CO6230989A2 CO 6230989 A2 CO6230989 A2 CO 6230989A2 CO 09103181 A CO09103181 A CO 09103181A CO 09103181 A CO09103181 A CO 09103181A CO 6230989 A2 CO6230989 A2 CO 6230989A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- haloalkoxy
- haloalkyl
- alkoxy
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1.- Compuestos quinolina CARACTERIZADOS PORQUE responden a la fórmula (I)en donde R es una porción de fórmulaen donde A es una unión química, CHR5 o CH2CHR5 ;R1 es hidrógeno, C1-C4-alquilo, C1-C4-haloalquilo, C1-C4-alcoxi o C1-C4-haloalcoxi; R2 es hidrógeno, C1-C4-alquilo, C1-C4-haloalquilo, C1-C4-alcoxi o C1-C4-haloalcoxi; R3 es hidrógeno o C1-C4-alquilo; R1 y R3 juntos también pueden ser C1-C4-alquileno lineal, el cual puede contener 1 o 2 radicales R6; R4 es hidrógeno, C1-C6-alquilo, C1-C6-hidroxialquilo, C1-C6-haloalquilo, C1-C6-alcoxi-C1-C4-alquilo, C1-C6-haloalcoxi-C1-C4-alquilo, C3-C6-cicloalquilo, C3-C6-halo-ciclo-alquilo, C3-C6-cicloalquil-C1-C4-alquilo, aril-C1-C4- alquilo, hetaril-C1-C4-alquilo, C3-C6-alquenilo, C3-C6-haloalquenilo, formilo, C1-C4-alquilcarbonilo o C1-C4-alcoxicarbonilo; R5 es hidrógeno, C1-C4-alquilo, C1-C4-haloalquilo, C1-C4-alcoxi o C1-C4-haloalcoxi; R1 y R5 juntos también pueden ser una unión simple, C1-C4-alquileno lineal, el cual puede contener 1 o 2 radicales R7; o R3 y R5 juntos también pueden ser C1-C4-alquileno lineal, el cual puede contener 1 o 2 radicales R8; R6 es C1-C4-alquilo, C1-C4-haloalquilo, C1-C4-alcoxi o C1-C4- haloalcoxi; o R5 y R6 juntos también pueden ser C1-C4-alquileno lineal, el cual puede contener 1 o 2 radicales R9; R7, R8 y R9 se seleccionan en forma independiente entre el grupo que consiste de C1-C4-alquilo, C1-C4-haloalquilo, C1-C4-alcoxi y C1-C4-haloalcoxi: n es 0, 1 o 2; m es 0, 1, 2 o 3; Ra, Rb se seleccionan en forma independiente entre el grupo que consiste de halógeno, CN, C1-C4-alquilo, C1-C4-haloalquilo, C1-C4-alcoxi, C1-C4-haloalcoxi, C(O)Raa, C(O)NRccRbb y NRccRbb; ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07104806 | 2007-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6230989A2 true CO6230989A2 (es) | 2010-12-20 |
Family
ID=39620293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09103181A CO6230989A2 (es) | 2007-03-23 | 2009-09-22 | Compuestos de quinolina apropiados para tratar transtornos que responden a la modulacion del receptor de serotonina 5-ht6 |
Country Status (25)
Country | Link |
---|---|
US (1) | US8242102B2 (es) |
EP (1) | EP2139880B1 (es) |
JP (1) | JP5538907B2 (es) |
KR (1) | KR20090128426A (es) |
CN (1) | CN101679351B (es) |
AR (1) | AR068381A1 (es) |
AT (1) | ATE524456T1 (es) |
AU (1) | AU2008231787A1 (es) |
BR (1) | BRPI0809081A2 (es) |
CA (1) | CA2681030C (es) |
CO (1) | CO6230989A2 (es) |
CR (1) | CR11039A (es) |
DO (1) | DOP2009000228A (es) |
EC (1) | ECSP099651A (es) |
ES (1) | ES2373617T3 (es) |
HK (1) | HK1139933A1 (es) |
IL (1) | IL201105A0 (es) |
MX (1) | MX2009010243A (es) |
NZ (1) | NZ579735A (es) |
PE (1) | PE20091187A1 (es) |
RU (1) | RU2009139073A (es) |
TW (1) | TW200940524A (es) |
UA (1) | UA97837C2 (es) |
UY (1) | UY31326A (es) |
WO (1) | WO2008116831A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140120036A1 (en) * | 2012-01-06 | 2014-05-01 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
US20130343993A1 (en) * | 2012-01-06 | 2013-12-26 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
AR106515A1 (es) * | 2015-10-29 | 2018-01-24 | Bayer Cropscience Ag | Sililfenoxiheterociclos trisustituidos y análogos |
WO2017157929A1 (en) * | 2016-03-14 | 2017-09-21 | AbbVie Deutschland GmbH & Co. KG | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
CN109053524A (zh) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种N-Boc-3-羟基氮杂环丁烷的制备方法 |
CN109503449A (zh) * | 2018-12-17 | 2019-03-22 | 天津药明康德新药开发有限公司 | 一种3-硝基吖丁啶-1-甲酸叔丁酯的合成方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6868700A (en) * | 1999-09-02 | 2001-04-10 | Wakunaga Pharmaceutical Co., Ltd | Quinolinecarboxylic acid derivative or its salt |
JP2003277416A (ja) * | 2002-03-22 | 2003-10-02 | Daiyanitorikkusu Kk | 糖類を含むアクリルアミド水溶液 |
AR039127A1 (es) * | 2002-03-27 | 2005-02-09 | Glaxo Group Ltd | Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento |
WO2003082286A1 (en) | 2002-04-03 | 2003-10-09 | Chemon Inc. | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same |
KR100657056B1 (ko) | 2002-06-05 | 2006-12-13 | 에프. 호프만-라 로슈 아게 | 중추 신경계 장애의 치료를 위한 5-ht6-수용체조절제로서 1-설폰일-4-아미노알콕시 인돌 유도체 |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7227023B2 (en) | 2003-04-30 | 2007-06-05 | Wyeth | Quinoline 3-amino chroman derivatives |
GB0321473D0 (en) | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
GB0411421D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
DE602006013828D1 (en) * | 2005-07-27 | 2010-06-02 | Hoffmann La Roche | 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren |
GB0519765D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
WO2008113818A1 (en) | 2007-03-21 | 2008-09-25 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
-
2008
- 2008-03-20 AU AU2008231787A patent/AU2008231787A1/en not_active Abandoned
- 2008-03-20 JP JP2009554034A patent/JP5538907B2/ja not_active Expired - Fee Related
- 2008-03-20 NZ NZ579735A patent/NZ579735A/en not_active IP Right Cessation
- 2008-03-20 EP EP08735447A patent/EP2139880B1/en active Active
- 2008-03-20 CN CN200880017192.XA patent/CN101679351B/zh not_active Expired - Fee Related
- 2008-03-20 WO PCT/EP2008/053387 patent/WO2008116831A1/en active Application Filing
- 2008-03-20 KR KR1020097019918A patent/KR20090128426A/ko not_active Application Discontinuation
- 2008-03-20 ES ES08735447T patent/ES2373617T3/es active Active
- 2008-03-20 BR BRPI0809081A patent/BRPI0809081A2/pt not_active IP Right Cessation
- 2008-03-20 AT AT08735447T patent/ATE524456T1/de not_active IP Right Cessation
- 2008-03-20 MX MX2009010243A patent/MX2009010243A/es active IP Right Grant
- 2008-03-20 RU RU2009139073/04A patent/RU2009139073A/ru not_active Application Discontinuation
- 2008-03-20 CA CA2681030A patent/CA2681030C/en not_active Expired - Fee Related
- 2008-03-20 UA UAA200910698A patent/UA97837C2/ru unknown
- 2008-03-23 US US12/532,407 patent/US8242102B2/en not_active Expired - Fee Related
- 2008-09-02 TW TW097133636A patent/TW200940524A/zh unknown
- 2008-09-08 UY UY0001031326A patent/UY31326A/es not_active Application Discontinuation
- 2008-09-08 PE PE2008001568A patent/PE20091187A1/es not_active Application Discontinuation
- 2008-09-08 AR ARP080103894A patent/AR068381A1/es not_active Application Discontinuation
-
2009
- 2009-09-22 IL IL201105A patent/IL201105A0/en unknown
- 2009-09-22 DO DO2009000228A patent/DOP2009000228A/es unknown
- 2009-09-22 CO CO09103181A patent/CO6230989A2/es not_active Application Discontinuation
- 2009-09-23 CR CR11039A patent/CR11039A/es unknown
- 2009-09-23 EC EC2009009651A patent/ECSP099651A/es unknown
-
2010
- 2010-07-02 HK HK10106465.1A patent/HK1139933A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
UA97837C2 (ru) | 2012-03-26 |
CN101679351A (zh) | 2010-03-24 |
EP2139880A1 (en) | 2010-01-06 |
US20110009380A1 (en) | 2011-01-13 |
DOP2009000228A (es) | 2009-10-15 |
UY31326A (es) | 2009-11-10 |
EP2139880B1 (en) | 2011-09-14 |
MX2009010243A (es) | 2009-12-14 |
TW200940524A (en) | 2009-10-01 |
RU2009139073A (ru) | 2011-04-27 |
ES2373617T3 (es) | 2012-02-07 |
ECSP099651A (es) | 2009-10-30 |
BRPI0809081A2 (pt) | 2019-09-24 |
IL201105A0 (en) | 2010-05-17 |
PE20091187A1 (es) | 2009-09-06 |
JP2010521520A (ja) | 2010-06-24 |
JP5538907B2 (ja) | 2014-07-02 |
KR20090128426A (ko) | 2009-12-15 |
NZ579735A (en) | 2012-02-24 |
HK1139933A1 (en) | 2010-09-30 |
CA2681030C (en) | 2015-01-13 |
WO2008116831A1 (en) | 2008-10-02 |
AR068381A1 (es) | 2009-11-11 |
US8242102B2 (en) | 2012-08-14 |
CA2681030A1 (en) | 2008-10-02 |
AU2008231787A1 (en) | 2008-10-02 |
CN101679351B (zh) | 2015-01-07 |
CR11039A (es) | 2010-02-09 |
ATE524456T1 (de) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6230989A2 (es) | Compuestos de quinolina apropiados para tratar transtornos que responden a la modulacion del receptor de serotonina 5-ht6 | |
PE20070795A1 (es) | Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa | |
PE20061353A1 (es) | Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa | |
UY29446A1 (es) | Derivados de ciclopentapiridina y tetrahidroquinolina | |
DE602006007556D1 (de) | Heteroarylsulfonylstilbene als 5-ht2a-antagonisten | |
EA201100875A1 (ru) | Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов | |
MX2010003366A (es) | Derivados de piperidina y piperazina para el tratamiento de tumores. | |
PE20150230A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
ATE442347T1 (de) | Biphenylderivate als selektive agonisten des gamma-rar-rezeptors | |
TW200745028A (en) | Novel sulphonylpyrroles | |
PE20091073A1 (es) | Derivados de isoxazolo-piridina | |
CY1111733T1 (el) | Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri | |
TW200745027A (en) | Novel sulphonylpyrroles | |
SE0203713D0 (sv) | Novel compounds | |
EA201000395A1 (ru) | Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида | |
EA201001124A1 (ru) | Производные хинолина и их применение в качестве фунгицидов | |
PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
UA90706C2 (ru) | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний | |
AR067528A1 (es) | Eteres heterociclicos sustituidos y su uso en trastornos del snc | |
EA201101060A1 (ru) | Новые гербициды | |
CO6251268A2 (es) | Compuestos que quinolina adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de serotonina 5 ht6 | |
NO20075273L (no) | Nye forbindelser | |
EA201101148A1 (ru) | Новые гербициды | |
EA201101146A1 (ru) | Новые гербициды |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |